Virus-like particles (VLPs) have become key tools in biology, medicine and even
engineering. After their initial use to resolve viral structures at the atomic level, VLPs were …

Virus-like particles (VLPs) have been shown to be strong activators of dendritic cells (DCs).
DCs are the most potent antigen presenting cells (APCs) and their activation prompts the …

Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from
soluble recombinant antigens by stronger protective immunogenicity associated with the …

Cancer is the second leading cause of death worldwide, and it is estimated that Human
papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV …

Links between human papillomaviruses (HPVs) and cervical cancer were first suspected
almost 30 years ago. DNA of specific HPV types has since been found in almost all cervical …

Abstract European Guidelines for Quality Assurance in Cervical Cancer Screening have
been initiated in the Europe Against Cancer Programme. The first edition established the …

Virus-like particles (VLPs) are self-assembled viral protein complexes that mimic the native
virus structure without being infectious. VLPs, similarly to wild type viruses, are able to …

Approximately 4 million persons in the United States and probably more than 100 million
persons worldwide are infected with hepatitis C virus. The virus has the unique ability to …

The papillomavirus major late protein, L1, forms the pentameric assembly unit of the viral
shell. Recombinant HPV16 L1 pentamers assemble in vitro into capsid-like structures, and …

Peptide-based vaccines aimed at the induction of effective T cell responses against
established cancers have so far only met with limited clinical success and clearly need to be …